Eli Lilly Raises 2026 Revenue Outlook 3% as Mounjaro and Zepbound Drive 48% Growth
Updated
Updated · Trefis · Aug 24
Eli Lilly Raises 2026 Revenue Outlook 3% as Mounjaro and Zepbound Drive 48% Growth
2 articles · Updated · Trefis · Aug 24
Summary
Eli Lilly lifted its full-year 2026 revenue guidance by 3% and raised its performance margin target by 2 percentage points, signaling confidence in a stronger year despite a modest EPS trim.
Revenue jumped 48% year over year in the latest quarter, powered by blockbuster demand for Mounjaro and Zepbound, giving the drugmaker room to add billions to its top-line forecast.
Shares rose 4.9% on earnings day and another 7.5% afterward, but investors are still probing for signs of slowing momentum after the stock's 79% gain over the past year.
Analysts have flagged a slower-than-expected Foundayo launch and guidance that may imply weaker growth in the second half, even as options markets show little alarm with implied volatility at 32%.